Last reviewed · How we verify

Nazmy Edward Seif — Portfolio Competitive Intelligence Brief

Nazmy Edward Seif pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Bupivacaine 0.5% (hyperbaric) Bupivacaine 0.5% (hyperbaric) marketed Local anesthetic (amide class) Voltage-gated sodium channels Anesthesia

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Başakşehir Çam & Sakura City Hospital · 1 shared drug class
  2. Bozyaka Training and Research Hospital · 1 shared drug class
  3. Bursa City Hospital · 1 shared drug class
  4. Centre of Postgraduate Medical Education · 1 shared drug class
  5. Clinique Saint-Jean, Bruxelles · 1 shared drug class
  6. Complejo Hospitalario Universitario de Granada · 1 shared drug class
  7. Federal University of Minas Gerais · 1 shared drug class
  8. Ain Shams University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Nazmy Edward Seif:

Cite this brief

Drug Landscape (2026). Nazmy Edward Seif — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nazmy-edward-seif. Accessed 2026-05-16.

Related